Mesoblast (MESO) said late Wednesday that its Ryoncil mesenchymal stromal cell therapy is now available for purchase in the US.
Ryoncil is approved for treatment of pediatric patients aged two months and above, including adolescents and teenagers, with steroid-refractory acute graft versus host disease, a condition with high mortality rates.
The company said it will sign a national drug rebate agreement with Medicaid and expects to be enrolled in the program in short order.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.